RPRX Stock News 15.90 05/13/2014 08:31:14 Repros Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Repros Therapeutics Inc (RPRX) 15.90 $RPRX

Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 8:15AM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2014.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX
PR Newswire - Mon May 05, 6:00PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Repros Therapeutics, Inc. ("Repros" or the "Company" (NASDAQ: RPRX) (CUSIP: 76028H209). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel
GlobeNewswire - Wed Apr 30, 3:12PM CDT
-- Co-primary endpoints of better maintenance of normal sperm concentration and smaller decline in sperm concentration, both compared to topical gel

Repros Completes Enrollment for Androxal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:15PM CDT
Repros Therapeutics announced it has completed enrollment for one of the two head-to-head studies on its secondary hypogonadism candidate, Androxal.

Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel
GlobeNewswire - Mon Apr 14, 9:34AM CDT
-- Company expects topline results by October 2014

Repros Provides Proellex Update - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:10PM CDT
Repros Therapeutics announced that it has received guidance from the FDA related to Proellex.

Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis
GlobeNewswire - Mon Mar 17, 8:20AM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today reported it has received guidance from the FDA indicating that Repros may proceed to conduct Phase 1 and 2 studies of oral Proellex under two separate INDs for endometriosis and uterine fibroids, while remaining on partial clinical hold. The FDA guidance provides that the highest allowed dose will be 12 mg daily. Repros is currently conducting a Phase 2 study for the use of Proellex in severe endometriosis and plans to submit a Phase 2 protocol for the treatment of symptomatic fibroids.

Narrower-than-Expected Q4 Loss at Repros - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:50AM CDT
Repros fourth quarter 2013 loss of 31 cents per share was narrower than the year-ago loss of 47 cents.

Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Thu Mar 13, 8:15AM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2013.

Bullish Two Hundred Day Moving Average Cross - RPRX
MarketNewsVideo.com - Tue Feb 18, 3:38PM CST
In trading on Tuesday, shares of Repros Therapeutics Inc crossed above their 200 day moving average of $19.54, changing hands as high as $19.87 per share. Repros Therapeutics Inc shares are currently trading up about 6% on the day.

Data on Repros' Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 5:26PM CST
Repros Therapeutics recently released additional results from its phase III study, ZA-300, on candidate Androxal.

Repros Therapeutics (RPRX) Jumps: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:46AM CST
Repros Therapeutics was a big mover last session, with shares rising over 6%.

Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism
GlobeNewswire - Mon Feb 10, 8:39AM CST
-- Greater Than 80% of Men Obtained T in the Normal Range

This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the  SPDR S&P Biotech Index  up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...

Repros Shares Soar After FDA Meeting - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 9:27AM CST
Share price of Repros surged 15.8% after its meeting with the FDA on Androxal

Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...

Nasdaq stocks posting largest percentage increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Why Repros Therapeutics, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 06, 2:11PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Repros Therapeutics , a clinical-stage...

Repros Therapeutics rises on Androxal update
AP - Thu Feb 06, 10:35AM CST
NEW YORK (AP) — Shares of Repros Therapeutics jumped Thursday after the company said it doesn't think it will have to run additional safety studies of its testosterone drug Androxal.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 51

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 140

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 89

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 190

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 71

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 188

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading

Top 5 Most Recently Viewed Articles

Stocks Rebound in Volatile Trading After Major Sell-off

Updated Category Markets Views 525

Global Stocks See Slight Uptick Amid Market Volatility Tuesday saw global stocks climb, yet trading was erratic. Following Monday's forceful selloff, investors remained wary. Officials of central banks aimed at reassuring the markets. Some respite came from Tokyo overnight's 10% rebound in Nikkei. Investor mood was still wary, though. U.S. stock futures displayed mixed...

Continue Reading
Projecting the Growth of the Femtech Market Through 2031

Updated Category News Views 77

The Femtech market stood at an impressive USD 33.92 billion back in 2023, setting the stage for its remarkable leap to a projected value of USD 113.53 billion by 2031. That’s a compound annual growth rate (CAGR) of about 16.3%. So, what's fueling this explosion? For starters, it's all about the rising awareness surrounding women's health issues—a topic that finally...

Continue Reading
Vestis Corporation Class Action Lawsuit: Key Details to Know

Updated Category News Views 494

Class Action Lawsuit Against Vestis Corporation Pomerantz LLP is drawing attention to a class action lawsuit filed against Vestis Corporation (NYSE: VSTS) concerning allegations of securities fraud. Investors who have incurred losses due to their investment in Vestis are encouraged to take action. Deadline for Investors Investors have until August 8, 2025, to request the...

Continue Reading
Associated Banc-Corp Sets Public Offering for Growth Funding

Updated Category News Views 215

Associated Banc-Corp Announces Stock Offering Associated Banc-Corp (NYSE: ASB) has recently made headlines with its announcement regarding a public offering of its common stock. The company is set to offer 12 million shares, each with a par value of $0.01, at a price of $25.00 per share. This means the total gross proceeds from this offering are expected to reach an...

Continue Reading
Olaplex Holdings Inc. to Engage at Canaccord Genuity Growth Conference

Updated Category News Views 138

Olaplex Holdings Inc. to Engage at Canaccord Genuity Growth Conference Olaplex Holdings, Inc. (NASDAQ: OLPX) has recently confirmed its engagement in the Canaccord Genuity 45th Annual Growth Conference. This prestigious event is set to take place soon, where the company will have a platform to showcase its commitment to innovation in the beauty and hair care industry....

Continue Reading